## 5 Conclusions  
Based on our results and findings, we can confirm a good correlation between troponins T and I in different forms of ACS. Both cTnI and cTnT are good markers of myocardial ischemia, as our study showed that both are most frequently elevated when a diagnosis of myocardial infarction is made. The more specific marker of myocardial ischemia was cTnI, as it appears more rapidly in the blood after cardiac injury. We observed that all patients with different troponin elevation levels had elevated cTnI only, regardless of the final diagnosis. It is important to note that our findings were reached by analyzing a small patient population (n = 119), so the results do not give a completely correct picture of cardiac troponin elevation in acute coronary events. A larger study including a larger number of patients would be needed for a more accurate assessment. Troponin I may be a more helpful marker of myocardial damage than cTnT in some particular situations. The troponin test has become much more sensitive in recent years, and it can now detect much lower levels of troponin in the blood than in the past. This enhanced sensitivity allows for quicker diagnosis of a heart attack and is especially helpful in cases where patients' symptoms are ill-defined or other tests yield conflicting results. Both cTnI and cTnT have similar detection efficiencies, particularly when these biomarkers are measured with high-sensitivity techniques. The latest global guidelines advise employing high-sensitivity techniques to evaluate both cTnI and cTnT in order to differentiate between acute coronary syndromes and detect myocardial damage. The ability of these high-sensitivity techniques to identify even minute variations in these biomarkers' concentrations enables a more accurate evaluation of heart damage. The accurate detection of both cTnI and T in the blood is ensured by the use of monoclonal antibodies specific for cardiac troponin, which have very little cross-reactivity with troponins from skeletal muscle. Their effectiveness in identifying cardiac damage is attributed to their specificity and accuracy. For this aim, elevations in cTnT and cTnI are valuable diagnostic tools in acute clinical situations, and the majority of the evidence indicates that the tests function similarly in patients. The general public's interest in using these assays to anticipate future occurrences is, nevertheless, beginning to develop. It's still unclear what the best strategy is for using the troponin assay wisely to enhance care for people who appear to be in good health. On the other hand, new data implies that choosing a specific troponin test for a certain clinical task could play a significant role in future clinical decision-making. Conceptualization, J.O. and H.M.; methodology, A.B. ; validation, A.J. ; formal analysis, A.B. and A.J. ; investigation, L.L. ; resources, J.O. ; data curation, H.M. and L.L. ; writing--original draft preparation, J.O. ; writing--review and editing, J.O., H.M., L.L., and A.J. ; supervision, A.J. and H.M.; project administration, J.O. ; funding acquisition, J.O. All authors have read and agreed to the published version of the manuscript. This research received no external funding. The observational, prospective, single-center study conducted between March and May 2023 was registered as an internal research project No. 20200198 at the University Medical Centre Ljubljana. The study was conducted in accordance with the Declaration of Helsinki, and approved by the Republic of Slovenia National Medical Ethics Committee (approval No. 0120-405/2020-3). Informed Consent Statement: Informed consent was obtained from all subjects involved in the study. The raw data supporting the conclusions of this article will be made available by the authors upon request. The authors would like to thank [PERSON] and [PERSON] from University Medical Centre Ljubljana, Institute of Clinical Chemistry and Biochemistry for the technical support. The authors declare no conflicts of interest.